Insmed Q2 FY26 net loss narrows to $13.2 million; revenue rises 296% to $425.5 million

Reuters2026/08/06 11:18

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Insmed posted Q2 2026 revenue of $425.5 million, up 296% from Q2 2025, driven by BRINSUPRI revenue of $309.2 million.
Net loss narrowed to $13.2 million, or $0.06 per share, from a $321.7 million loss a year earlier.
R&D expense rose to $210 million from $177.2 million, while SG&A climbed to $247.5 million from $154.8 million.
BRINSUPRI revenue grew 49% versus Q1 2026; ARIKAYCE revenue increased 8% versus Q2 2025 to $116.3 million.
Raised 2026 BRINSUPRI revenue guidance to $1.25 billion-$1.4 billion; reiterated 2026 ARIKAYCE guidance of $450 million-$470 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Insmed Inc. published the original content used to generate this news brief on August 06, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Insmed Q2 FY26 net loss narrows to $13.2 million; revenue rises 296% to $425.5 million

You may also like

Crypto prices